Literature DB >> 18335191

[Adherence to neurologic treatment. Lessons from multiple sclerosis].

S Kern1, H Reichmann, T Ziemssen.   

Abstract

In light of increasing prevalence rates of chronic conditions and a growing elderly population, patients' nonadherence to medical regimes reflects a significant problem in modern health care. In the past, patients were primarily held responsible for problematic adherence. Over the past decades this attitude has changed dramatically, and it is now acknowledged that lack of adherence reflects a problem requiring different approaches and interventions on many different levels. Here we highlight central aspects and consequences of adherence problems in long-term therapy. Factors affecting treatment motivation in multiple sclerosis patients are summarized focusing on neurologic treatment issues, and specific intervention strategies for patients, doctors, and nurses are discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18335191     DOI: 10.1007/s00115-008-2419-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  66 in total

Review 1.  Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

Authors:  Helen L Tremlett; Joel Oger
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

2.  Factors related to medication adherence in memory disorder clinic patients.

Authors:  R L Ownby; C Hertzog; E Crocco; R Duara
Journal:  Aging Ment Health       Date:  2006-07       Impact factor: 3.658

3.  Medication adherence and cognition. Medical, personal and economic factors influence level of adherence in older adults.

Authors:  Raymond L Ownby
Journal:  Geriatrics       Date:  2006-02

Review 4.  Assessing medication adherence in the elderly: which tools to use in clinical practice?

Authors:  Eric J MacLaughlin; Cynthia L Raehl; Angela K Treadway; Teresa L Sterling; Dennis P Zoller; Chester A Bond
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

5.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.

Authors:  Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

6.  Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.

Authors:  J Y Lee; J W Kusek; P G Greene; S Bernhard; K Norris; D Smith; B Wilkening; J T Wright
Journal:  Am J Hypertens       Date:  1996-08       Impact factor: 2.689

7.  The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis.

Authors:  L Julian; N M Merluzzi; D C Mohr
Journal:  Mult Scler       Date:  2007-01       Impact factor: 6.312

8.  Costs and quality of life of multiple sclerosis in Germany.

Authors:  Gisela Kobelt; Jenny Berg; Peter Lindgren; W G Elias; P Flachenecker; M Freidel; N König; V Limmroth; E Straube
Journal:  Eur J Health Econ       Date:  2006-09

Review 9.  Interventions to enhance medication adherence.

Authors:  R B Haynes; X Yao; A Degani; S Kripalani; A Garg; H P McDonald
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

10.  Physician recognition of behavioral, psychological, and social aspects of medical care.

Authors:  D S Brody
Journal:  Arch Intern Med       Date:  1980-10
View more
  11 in total

Review 1.  Compliance, adherence, and the treatment of multiple sclerosis.

Authors:  Thomas Klauer; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

2.  QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.

Authors:  Tjalf Ziemssen; Pasquale Calabrese; Iris-Katharina Penner; Rainer Apfel
Journal:  J Neurol       Date:  2016-02-25       Impact factor: 4.849

3.  Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.

Authors:  Christian Bischoff; H Schreiber; A Bergmann
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

4.  [Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].

Authors:  J Haas; R A Linker; H P Hartung; M Meergans; S Ortler; F Tracik
Journal:  Nervenarzt       Date:  2012-12       Impact factor: 1.214

5.  Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey.

Authors:  Rocco Haase; Jennifer S Kullmann; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-15       Impact factor: 6.570

6.  Improving patient-physician dialog: commentary on the results of the MS Choices survey.

Authors:  Alessandra Lugaresi; Tjalf Ziemssen; Celia Oreja-Guevara; Delyth Thomas; Elisabetta Verdun
Journal:  Patient Prefer Adherence       Date:  2012-02-17       Impact factor: 2.711

7.  Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.

Authors:  Tjalf Ziemssen; Michael Lang; Stephan Schmidt; Holger Albrecht; Luisa Klotz; Judith Haas; Christoph Lassek; Stefan Lang; Veronika E Winkelmann; Benjamin Ettle; Ulf Schulze-Topphoff
Journal:  J Neurol       Date:  2022-01-04       Impact factor: 6.682

8.  Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.

Authors:  Uwe K Zettl; Ulrike Bauer-Steinhusen; Thomas Glaser; Klaus Hechenbichler; Volker Limmroth
Journal:  BMC Neurol       Date:  2013-09-06       Impact factor: 2.474

9.  Acceptance of the extracare program by Beta interferon-treated patients with multiple sclerosis: results of the explore study.

Authors:  Matthias Freidel; Sonja Ortler; Alexander Fuchs; Sabine Seibert; Katrin Schuh
Journal:  J Neurosci Nurs       Date:  2015-02       Impact factor: 1.230

10.  Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany.

Authors:  Veit Becker; Volker Heeschen; Katrin Schuh; Heinke Schieb; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2018-01-23       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.